5-Amino-1MQ and MOTS-c appear together in metabolic research discussions, which invites the assumption that they are alternatives. They are not even the same kind of molecule – one is a small-molecule enzyme inhibitor and the other is a peptide encoded in mitochondrial DNA.
- 5-Amino-1MQ
- Small-molecule NNMT inhibitor
- MOTS-c
- Mitochondrial-derived peptide
- Shared area
- Metabolic signalling research
- Not shared
- Compound class or mechanism
The short answer
5-Amino-1MQ is a small molecule studied as an inhibitor of NNMT, an enzyme. MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA and studied as a signalling molecule. The research areas overlap; the compound classes and described mechanisms do not.
| 5-Amino-1MQ | MOTS-c | |
|---|---|---|
| Compound class | Small molecule | Peptide (16 amino acids) |
| Target | NNMT enzyme | Metabolic signalling pathways |
| Origin | Synthetic | Encoded in mitochondrial DNA |
| Mechanism studied | Enzyme inhibition | Mitochondria-to-nucleus signalling |
| Evidence stage | Early, mostly the target not the inhibitor | Mechanistic, preclinical |
5-Amino-1MQ: inhibiting an enzyme
NNMT is an enzyme that has attracted research attention in metabolic contexts, and 5-Amino-1MQ is studied as an inhibitor of it. An important caveat applies here: much of the surrounding literature concerns the NNMT target in general rather than this specific inhibitor. The distinction matters, because interest in a target is not evidence for a particular molecule that acts on it, and this compound is best regarded as an early-stage research tool.
MOTS-c: a peptide signal
MOTS-c is encoded inside mitochondrial DNA rather than the nucleus, and published mechanistic work describes it as a retrograde signal from mitochondrion to cell. Its literature is mechanistic and largely preclinical, built on cell-model and rodent studies.
Why the comparison is asked at all
Both appear in metabolic research, and both are relatively recent additions to that field. That is the extent of the overlap. A small-molecule enzyme inhibitor and a mitochondrial-derived signalling peptide are not substitutes for one another, and the published literature does not present them as alternatives.
Evidence quality
Neither has a substantial published human trial record. MOTS-c has a mechanistic literature centred on the peptide itself; 5-Amino-1MQ has a thinner direct literature with much of the surrounding work addressing its target rather than the compound. Research designs should account for that asymmetry.
Compounds referenced here are supplied as analytical-grade reference materials for in-vitro and laboratory research only. Nothing on this page is a recommendation for human or veterinary use.
Studies cited
- Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells (Journal of Obstetrics and Gynaecology, 2021)
- Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice (Scientific Reports, 2022)
- NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy (Journal for ImmunoTherapy of Cancer, 2024)
- MOTS-c and metabolic disorders (Metabolites, 2023)
- MOTS-c and muscle-atrophy signaling (American journal of physiology. Endocrinology and metabolism, 2021)
- MOTS-c mitochondrial peptide — therapeutic overview (Frontiers in endocrinology, 2023)
Questions
What is the difference between 5-Amino-1MQ and MOTS-c?
5-Amino-1MQ is a small molecule studied as an inhibitor of the enzyme NNMT. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA and studied as a signalling molecule. They are different classes of compound with different described mechanisms.
Is 5-Amino-1MQ a peptide?
No. 5-Amino-1MQ is a small molecule, not a peptide. It is grouped with peptides in research catalogs because it appears in overlapping metabolic research, not because it shares their structure.
How strong is the evidence for 5-Amino-1MQ?
The direct evidence is limited. Much of the surrounding literature concerns the NNMT target generally rather than this specific inhibitor, and interest in a target is not evidence for a particular molecule acting on it. It is best regarded as an early-stage research tool.
Are 5-Amino-1MQ and MOTS-c studied for the same purpose?
Both appear in metabolic research, but they are different compound classes with different mechanisms, and the published literature does not present them as alternatives to one another.
For laboratory research and educational purposes only. Not medical advice. The materials discussed are not for human or animal consumption and have not been evaluated by the FDA.